04 · Five things to know · 02

Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Must read

What happened

In a late-breaker at ENA 2026, Revolution Medicines reported updated Phase 1/2 data for Rasonque (daraxonrasib), 200 mg, with gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic cancer. In 61 patients followed for a median of 18.3 months, 60.7% had a confirmed response (95% CI 47.3 to 72.9). Complete responses were 8.2%. Median progression-free survival was 12.8 months and the 12-month overall survival rate 76.6%. The company called the safety consistent with the known profiles and gave no grade 3 or higher rates in its release. The randomized Phase 3 RASolute 303 is ongoing. Claim

Why it matters

FDA approved daraxonrasib on 08.26.2026 for metastatic pancreatic cancer after prior systemic therapy, or when multiagent therapy is not an option. These first-line numbers come from one arm with no comparator, so they cannot be set against chemotherapy alone. Analysis

What we’re watching

RASolute 303’s readout and the grade 3 or higher toxicity of the combination.

Claim CheckPartial

CLAIM CHECK

Partial The release gives no registry number. The matching study we found, NCT06445062, a platform trial, registers adverse events and dose-limiting toxicities as primaries for this combination; response and survival are secondaries.

Sources

Also in Five things to know

Bookmarks need a Mind Club sign-in. How sign-in works

Read it in Five things to know